BASF, one of the world’s leading chemical companies, and Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced recently a new collaboration focusing on the development of novel insecticides based on new binding areas (Site-of-Action or ‘SoA’) on key insecticidal target proteins. The parties also announced that the collaboration achieved its first project milestone, with the joint nomination of a set of novel SoAs, discovered by Evogene that will advance to the discovery phase of relevant bioactive compounds.
BASF, one of the world’s leading chemical companies, and Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced recently a new collaboration focusing on the development of novel insecticides based on new binding areas (Site-of-Action or ‘SoA’) on key insecticidal target proteins. The parties also announced that the collaboration achieved its first project milestone, with the joint nomination of a set of novel SoAs, discovered by Evogene that will advance to the discovery phase of relevant bioactive compounds.
In the initial phase of the collaboration, using their strong background in computational methods, Evogene has developed a smart process to identify potential novel compounds that act on new proteins and binding sites.
“Insecticides are essential for controlling insect damage and infestations that affect public health and increase the quality and quantity of crops. I am excited that we have achieved our first milestone towards the discovery and development of new insecticides,” said Eran Kosover, Executive Vice President and General Manager of the Ag-Chemicals division at Evogene Ltd. “This marks an important step in establishing Evogene’s Ag-Chemicals division entry into Insecticides, and an important extension of our relationship with BASF, a world leader in agricultural solutions.”
See full article at Agropages